Investor Update
Basel, 3 April 2003
European Approval
for Use of NeoRecormon Once Every Two Weeks in Renal Anaemia
Major patient benefit:
New dosing regimen offers dialysis patients anaemia therapy with half as many injections
Roche announced today that the European Commission has granted marketing approval for use of subcutaneous NeoRecormon (epoetin beta) once every two weeks in patients with renal anaemia undergoing dialysis. This new regimen cuts by half the number of injections and provides the efficacy and safety benefits seen previously with once-weekly administration1.
Anaemia correction, as measured by haemoglobin levels, is effectively maintained when patients who are stable on a once weekly regimen of subcutaneous NeoRecormon are switched to once every two weeks administration. Clinical benefits and tolerability of the once every two weeks regimen is in-line with the well-established efficacy and safety profile of NeoRecormon once weekly, which has been gained over 12 years of clinical experience. Moreover, a less frequent dosing regimen is expected to result in significant cost savings, reducing nursing time and may improve patients compliance.
Professor Boleslaw Rutkowski from the Medical University School in Gdansk, Poland and a lead investigator in the European Collaborative Group which carried out the clinical study on which marketing approval is based, commented: “Reducing the frequency of subcutaneous administration of NeoRecormon to a once every two week regimen has a number of known and potential benefits. Importantly, it significantly reduces the number of injections patients need, encourages patient independence and is more convenient for both home and clinic administration.”
“This is excellent news since this new dosing regimen will significantly improve the quality of life for dialysis patients with renal anaemia. Additionally, this approval reconfirms the efficacy and safety benefits of NeoRecormon, Roche’s leading anaemia therapy”, said William Burns, Head of Roche Pharma.
Maintaining target haemoglobin levels decreases the risk of hospitalisation in patients with chronic renal disease2, and studies also demonstrate that there are concrete benefits in terms of improved cardiac structure and function, as well as decreased co-morbidities and the risk of death3,4,5. An analysis of a cohort of over 3000 dialysis patients showed a significant reduction of 20% in all-cause mortality in the first year of treatment with NeoRecormon6.
President of the British Renal Society, Dr Donal O’Donoghue said “Treatment strategies that make epoetin administration more convenient for patients are welcomed. For many patients the new once every two weeks NeoRecormon regimen will encourage greater adherence with their anaemia therapy which is important in terms of improving day to day quality of life. Moreover, it may contribute to reducing life threatening cardiac complications, which represent a major risk of mortality in dialysis patients.”
About Roche
Headquartered in Basel, Switzerland, Roche is an innovation driven global healthcare
leader focused on pharmaceuticals and diagnostics. Roche is world-wide number one in diagnostics, oncology
and transplantation and has a leading position in Virology. With products and services that address
the prevention, diagnosis and treatment of diseases, the company contributes broadly to the enhancement
of people’s health and quality of life. Roche employs some 62 000 people in more than 150 countries
around the world. The company has business alliances and R&D relationships with numerous partners,
including majority ownership interests in Genentech and Chugai, which are both members of the Roche
Group.
All trademarks used or mentioned in this release are legally protected.
References:
1
Locatelli F et al,. Am J Kidney Dis 2002 Jul;40(1):119-25
2 Xia H, Ebben J, Ma JZ. J
Am Soc Nephrol 1999;10(6):1309-1316
3 Wizemann V, Schafer R, Kramer W. Nephron 1993;64:202-206
4
Ma JZ, Ebben J, Xia H et al. J Am Soc Nephrol 1999;10:610-619
5 Madore F, Lowrie EG,
Brugnara C. J Am Soc Nephrol 1997;8:1921-1929
6 Mocks J, et al. Nephron 2000 Dec;86(4):455-62